Works matching IS 09538194 AND DT 2025 AND VI 37 AND IP 2

Results: 7
    1

    Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors.

    Published in:
    Journal of Neuroendocrinology, 2025, v. 37, n. 2, p. 1, doi. 10.1111/jne.13485
    By:
    • Faggiano, Antongiulio;
    • Russo, Flaminia;
    • Zamponi, Virginia;
    • Sesti, Franz;
    • Puliani, Giulia;
    • Modica, Roberta;
    • Malandrino, Pasqualino;
    • Ferraù, Francesco;
    • Rinzivillo, Maria;
    • Di Muzio, Marco;
    • Di Simone, Emanuele;
    • Panattoni, Nicolò;
    • Dolce, Pasquale;
    • Lauretta, Rosa;
    • Di Iasi, Gianfranco;
    • Prinzi, Antonio;
    • Alessi, Ylenia;
    • Feola, Tiziana;
    • Mazzilli, Rossella;
    • Appetecchia, Marialuisa
    Publication type:
    Article
    2
    3
    4
    5
    6

    Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force.

    Published in:
    Journal of Neuroendocrinology, 2025, v. 37, n. 2, p. 1, doi. 10.1111/jne.13479
    By:
    • Prasad, Vikas;
    • Koumarianou, Anna;
    • Denecke, Timm;
    • Sundin, Anders;
    • Deroose, Christophe M.;
    • Pavel, Marianne;
    • Christ, Emanuel;
    • Lamarca, Angela;
    • Caplin, Martyn;
    • Castaño, Justo P.;
    • Dromain, Clarisse;
    • Falconi, Massimo;
    • Grozinsky‐Glasberg, Simona;
    • Hofland, Johannes;
    • Knigge, Ulrich Peter;
    • Kos‐Kudla, Beata;
    • Krishna, Balkundi A.;
    • Reed, Nicholas Simon;
    • Scarpa, Aldo;
    • Srirajaskanthan, Rajaventhan
    Publication type:
    Article
    7

    Issue Information.

    Published in:
    Journal of Neuroendocrinology, 2025, v. 37, n. 2, p. 1, doi. 10.1111/jne.13401
    Publication type:
    Article